Cargando…

Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis

INTRODUCTION: Association between elevated cytokeratin 18 (CK-18) levels and hepatocyte death has made circulating CK-18 a candidate biomarker to differentiate non-alcoholic fatty liver from non-alcoholic steatohepatitis (NASH). Yet studies produced variable diagnostic performance. We aimed to provi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jenny, Vali, Yasaman, Boursier, Jérôme, Duffin, Kevin, Verheij, Joanne, Brosnan, M. Julia, Zwinderman, Koos, Anstee, Quentin M., Bossuyt, Patrick M., Zafarmand, Mohammad Hadi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485872/ https://www.ncbi.nlm.nih.gov/pubmed/32915852 http://dx.doi.org/10.1371/journal.pone.0238717

Ejemplares similares

FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis
por: Vali, Yasaman, et al.
Publicado: (2021)

Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review
por: Lee, Jenny, et al.
Publicado: (2021)

Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease
por: Van Dijk, Anne-Marieke, et al.
Publicado: (2021)

Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study
por: Zhang, Huai, et al.
Publicado: (2023)

Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Mak, Anne Linde, et al.
Publicado: (2021)

Elevated Serum Level of Cytokeratin 18 M65ED Is an Independent Indicator of Cardiometabolic Disorders
por: Qian, Lingling, et al.
Publicado: (2020)

Development and evaluating multimarker models for guiding treatment decisions
por: Tajik, Parvin, et al.
Publicado: (2018)

Cytokeratin phosphorylation, cytokeratin filament severing and the solubilization of the maternal mRNA Vg1
Publicado: (1991)

Expression of M30 and M65 in celiac disease. Analyticalcross-sectional study
por: Aksoy, Evrim Kahramanoğlu, et al.
Publicado: (2018)

Serum Caspase-Cleaved Cytokeratin (M30) Indicates Severity of Liver Dysfunction and Predicts Liver Outcome
por: Oweira, Hani, et al.
Publicado: (2018)

Cytokeratin 18, Alanine Aminotransferase, Platelets and Triglycerides Predict the Presence of Nonalcoholic Steatohepatitis
por: Cao, Wei, et al.
Publicado: (2013)

Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study
por: Vali, Yasaman, et al.
Publicado: (2022)

Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease
por: Świderska, Magdalena, et al.
Publicado: (2017)

Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection
por: Benmassaoud, Amine, et al.
Publicado: (2018)

Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients
por: Huang, Jee-Fu, et al.
Publicado: (2017)

The Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (CK-18 M30) and Matrix Metalloproteinase 2 (MMP-2) Levels in Chronic Hepatitis B Patients with Cirrhosis
por: Sumer, Sua, et al.
Publicado: (2013)

Cytokeratin 20 mRNA in peripheral venous blood of colorectal carcinoma patients.
por: Funaki, N. O., et al.
Publicado: (1998)

Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression
por: Malek-Hosseini, Zahra, et al.
Publicado: (2016)

Serum Level of Cytokeratin 18 (M65) as a Prognostic Marker of High Cardiovascular Disease Risk in Individuals with Non-Alcoholic Fatty Liver Disease
por: Pagano, Sabrina, et al.
Publicado: (2023)

Application of weighting methods for presenting risk-of-bias assessments in systematic reviews of diagnostic test accuracy studies
por: Vali, Yasaman, et al.
Publicado: (2021)

Haematogenous cytokeratin 20 mRNA as a predictive marker for recurrence in oral cancer patients
por: Kawamata, H, et al.
Publicado: (1999)

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis
por: Twiss, James, et al.
Publicado: (2023)

Propofol or sevoflurane anaesthesia does not affect hepatic integrity as assessed by the M30 & M65 cell death markers & liver enzymes
por: Chondrogiannis, Konstantinos, et al.
Publicado: (2014)

Cytokeratin 17 mRNA as a prognostic marker of oral squamous cell carcinoma
por: Kitamura, Ryoji, et al.
Publicado: (2017)

Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study
por: Alhinai, Alshaima, et al.
Publicado: (2021)

Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis
por: Jacobson, Ira M., et al.
Publicado: (2022)

Limited Utility of Plasma M30 in Discriminating Non-Alcoholic Steatohepatitis from Steatosis – A Comparison with Routine Biochemical Markers
por: Chan, Wah-Kheong, et al.
Publicado: (2014)

Reporting of test comparisons in diagnostic accuracy studies: A literature review
por: Vali, Yasaman, et al.
Publicado: (2020)

A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis
por: Eguchi, Akiko, et al.
Publicado: (2022)

The roles of M30 and M65 in the assessment of treatment response and prognosis in patients with non-small cell lung cancer, who receive neoadjuvant treatment
por: Coskun, Belkıs Nihan, et al.
Publicado: (2019)

Quantification of Cytokeratin 5 mRNA Expression in the Circulation of Healthy Human Subjects and after Lung Transplantation
por: Nickerson, Derek W., et al.
Publicado: (2009)

Carcinoembryonic antigen and cytokeratin 20 in peritoneal cells of cancer patients: are we aware of what we are detecting by mRNA examination?
por: Kowalewska, M, et al.
Publicado: (2008)

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer
por: Daskalaki, A, et al.
Publicado: (2009)

Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions
por: Anstee, Quentin M., et al.
Publicado: (2021)

Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study
por: Doward, Lynda C., et al.
Publicado: (2020)

Stem Cell Markers (Cytokeratin 17 and Cytokeratin 19) in Scarring and Nonscarring Alopecia
por: El Sakka, Dalia, et al.
Publicado: (2016)

Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study
por: O'Hara, Jamie, et al.
Publicado: (2020)

Validation of droplet digital PCR for cytokeratin 19 mRNA detection in canine peripheral blood and mammary gland
por: Tanvetthayanont, Potsawat, et al.
Publicado: (2022)

Identification of relevant prognostic values of cytokeratin 20 and cytokeratin 7 expressions in lung cancer
por: Luo, Hai-Tao, et al.
Publicado: (2017)

Evaluation of Cytokeratin-7 and Cytokeratin-19 Expression Relationship with Gleason Score in Prostatic Adenocarcinoma
por: Soltanipur, Masood, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t6vu0h2jelap1but4trjg7i962